Sanctuary Advisors LLC Purchases Shares of 2,805 Medpace Holdings, Inc. $MEDP

Sanctuary Advisors LLC acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 2,805 shares of the company’s stock, valued at approximately $1,486,000.

Several other hedge funds also recently made changes to their positions in MEDP. Johnson Financial Group Inc. acquired a new stake in Medpace during the second quarter valued at approximately $27,000. Geneos Wealth Management Inc. grew its position in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the last quarter. Elyxium Wealth LLC bought a new position in shares of Medpace in the fourth quarter valued at $30,000. Allied Private Wealth LLC bought a new position in shares of Medpace in the second quarter valued at $31,000. Finally, Kilter Group LLC acquired a new stake in shares of Medpace during the 2nd quarter valued at $31,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Price Performance

MEDP stock opened at $619.05 on Thursday. The firm has a market capitalization of $17.28 billion, a P/E ratio of 36.29, a P/E/G ratio of 2.74 and a beta of 1.15. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The company’s 50 day simple moving average is $559.49 and its 200-day simple moving average is $493.31.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. During the same quarter last year, the business posted $3.10 EPS. The company’s revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Brian T. Carley sold 5,000 shares of Medpace stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the transaction, the director owned 27,825 shares in the company, valued at approximately $16,935,129.75. The trade was a 15.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Fred B. Davenport, Jr. sold 7,283 shares of the company’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $606.15, for a total value of $4,414,590.45. Following the transaction, the director directly owned 3,798 shares in the company, valued at $2,302,157.70. The trade was a 65.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 125,290 shares of company stock valued at $76,466,988. 20.50% of the stock is currently owned by company insiders.

Medpace News Summary

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace remains near a potential technical buy point of $628.92 after its July advance. The stock is trading well above its 50-day and 200-day moving averages, indicating sustained momentum. Medpace Stock Hovers Near Entry, Offers Second Chance After July Spike
• Positive Sentiment: The company’s latest quarterly results exceeded expectations: adjusted earnings were $4.25 per share versus the $3.98 consensus estimate, while revenue rose 17.2% year over year to $707.33 million, surpassing forecasts. Fiscal 2026 EPS guidance remains $17.25 to $17.95.
• Positive Sentiment: Institutional investors and hedge funds own approximately 78% of Medpace, and several investment firms have recently increased their positions. Some analysts have also raised price targets, including RBC’s $692 target and Mizuho’s $665 target.
• Neutral Sentiment: Value-focused investors are comparing Medpace with Concentra Group, but the available report does not establish a clear valuation advantage for MEDP. The stock trades at roughly 36 times earnings, with a PEG ratio above 2.7, suggesting investors are already paying a premium for growth. CON vs. MEDP: Which Stock Should Value Investors Buy Now?
• Neutral Sentiment: Reported short interest was zero shares, producing a zero-day days-to-cover ratio. This provides no meaningful evidence of short-covering demand or downside pressure.
• Negative Sentiment: Several executives have recently sold shares near $620–$625. CEO August Troendle sold 15,978 shares in two transactions worth approximately $9.97 million, while CFO Kevin Brady sold 3,400 shares valued at about $2.13 million. Although both executives retain shares, the concentration of insider selling could weigh on sentiment. Medpace CEO August Troendle Sells 1,983 Shares
• Negative Sentiment: Analyst opinion remains cautious overall: the consensus rating is “Hold,” and the average price target of $584.18 is below recent trading levels. This may make additional upside more difficult without another earnings or guidance catalyst.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on MEDP. TD Cowen raised their price objective on Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Royal Bank Of Canada boosted their target price on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Leerink Partners set a $620.00 target price on Medpace in a report on Thursday, July 23rd. BMO Capital Markets increased their price target on Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research report on Friday, July 24th. Finally, Robert W. Baird lifted their price target on Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $584.18.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.